J. Cassel & The Law Office of Hawke McKeon & Sniscak, LLP v. DOH (OOR)

CourtCommonwealth Court of Pennsylvania
DecidedJanuary 10, 2023
Docket491 C.D. 2022
StatusUnpublished

This text of J. Cassel & The Law Office of Hawke McKeon & Sniscak, LLP v. DOH (OOR) (J. Cassel & The Law Office of Hawke McKeon & Sniscak, LLP v. DOH (OOR)) is published on Counsel Stack Legal Research, covering Commonwealth Court of Pennsylvania primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
J. Cassel & The Law Office of Hawke McKeon & Sniscak, LLP v. DOH (OOR), (Pa. Ct. App. 2023).

Opinion

IN THE COMMONWEALTH COURT OF PENNSYLVANIA

Judith Cassel and The Law Office of : Hawke McKeon & Sniscak, LLP, : Petitioners : : v. : No. 491 C.D. 2022 : Department of Health (Office of : Open Records), : Respondent : Argued: December 12, 2022

BEFORE: HONORABLE CHRISTINE FIZZANO CANNON, Judge HONORABLE ELLEN CEISLER, Judge HONORABLE STACY WALLACE, Judge

OPINION NOT REPORTED

MEMORANDUM OPINION BY JUDGE CEISLER FILED: January 10, 2023

Judith Cassel and The Law Office of Hawke McKeon & Sniscak, LLP (collectively, Requesters) petitions this court for review of the Final Determination Upon Reconsideration (Final Determination) of the Office of Open Records (OOR), which concluded that records sought under the Right-to-Know Law (RTKL)1 were exempt from disclosure pursuant to Section 708(b)(17) of the RTKL2 as they related to the Department of Health’s (Department) non-criminal investigation into the safety of vaporized medical marijuana products (Products). The issues on appeal are whether the OOR erred in concluding that all records withheld by the Department related to its non-criminal investigation or, in the alternative, whether the records at issue were no longer exempt from disclosure once the Department revoked its

1 Act of February 14, 2008, P.L. 6, 65 P.S. §§ 67.101-67.3104.

2 65 P.S. § 67.708(b)(17). approval of certain Products. After careful review, we affirm in part and vacate in part the OOR’s Final Determination, in part, and remand this matter to the OOR for an in camera review of the Department’s records for purposes of determining the exemption status thereof. I. Background The parties do not dispute the underlying facts in this matter. On November 16, 2021, as part of a non-criminal investigation by the Department into Products that contain additives, Sunny Podolak (Podolak), Assistant Director and Chief Compliance Officer of the Department’s Office of Medical Marijuana (OMM), sent an email advising permitted medical marijuana growers and processors (Permittees) that they must submit any Products containing additives to the Department for approval, including Products that were previously approved.3 Reproduced Record (R.R.) at 80a. Podolak sent Permittees a subsequent email on December 13, 2021, requesting information about the determined safety of any additives used in their Products.4 Id. The responses provided by Permittees were used by the Department to evaluate Permittee compliance with the MMA, the Department’s regulations, and other applicable laws. Id. at 81a. At the conclusion of its review, the Department notified Permittees on February 4, 2022, that they could no longer sell any Products containing additives not approved for inhalation by the United States Food and Drug

3 Section 301(a)(1) of the Medical Marijuana Act (MMA), enacted by the Act of April 17, 2016, P.L. 84, as amended, 35 P.S. § 10231.301(a)(1), established a medical marijuana program that is implemented and administered by the Department. Section 301(a)(3) of the MMA explicitly grants the Department regulatory and enforcement authority over the growing, processing, sale, and use of medical marijuana. 35 P.S. § 10231.301(a)(3).

4 Podolak’s November 16 and December 12, 2021 emails do not appear in the certified record (C.R.) filed with this Court.

2 Administration (FDA) and that any such Products were subject to a mandatory recall. Id. On December 22, 2021, Requesters submitted a RTKL request (Request) with the Department, seeking “[a]ll documents, correspondence, and all other emails, including but not limited to, internal and external emails, reports, complaints, and notes” related to: 1. the OMM’s decision to use the FDA’s inactive ingredient database to approve medical marijuana products; 2. the OMM’s November 16, 2021 decision to require that Permittees submit Products for approval, including Products that were previously approved; 3. information that did not support the OMM’s November 16, 2021 decision; 4. any investigation made by the Department prior to November 16, 2021, regarding the safety of terpene blends as an additive in medical marijuana products; 5. the Department’s review of Products submitted for approval pursuant to Podolak’s November 16, 2021 email; 6. Podolak’s December 13, 2021 email to Permittees seeking information regarding the determined safety of additives used in Products; and 7. any material received in response to Podolak’s December 13, 2021 email. Id. at 6a-7a. On December 30, 2021, the Department advised Requesters that it was unable to locate any records responsive to Paragraph 1 of the Request. Id. at 9a. Although the Department provided records responsive to Paragraph 5 of the Request, it denied the Request with respect to Paragraphs 2-4, and 6-7, citing the exemption for non- criminal investigative records in Section 708(b)(17) of the RTKL. Id. at 9a-10a.

3 Requesters appealed to the OOR on January 20, 2022, arguing that the requested records were not exempt from disclosure under the RTKL or other legal authority. Id. at 24a. Requesters also challenged the Department’s claim that no responsive records existed with respect to Paragraph 1 of the Request, and that the Department had produced all records responsive to Paragraph 5 of the Request. Id. at 25a-26a. Requester asserted that, at a minimum, the Department should be required to submit an exemption log indicating how each responsive record related to its non-criminal investigation, followed by an in camera review by an appeals officer, who would determine the exemption status of each record. Id. at 26a. In its response to Requesters’ appeal, the Department submitted an affidavit from Lisa Keefer (Keefer), the Department’s Open Records Officer, in which Keefer detailed the process she undertook to identify the relevant records. Id. at 61a. After reviewing the results of her search, Keefer concluded there was “no reason to believe that the Department [had] responsive records to Paragraph 1 of the [R]equest within its custody or control.” Id. at 62a. The Department maintained that any responsive records it possessed were utilized to initiate and conduct a non-criminal investigation under the MMA. Id. at 52a, 54a-55a. In support, the Department submitted a February 4, 2022 affidavit from Podolak, who confirmed that the records sought in Paragraphs 2 and 4-7 of the Request related to the Department’s non-criminal investigations into the safety of Products containing additives. Id. at 65a-66a. As to Paragraph 3 of the Request, the Department argued that it was insufficiently specific under Section 703 of the RTKL, which requires that a written request for records “identify or describe the records sought with sufficient specificity to enable the agency to ascertain which records are being requested . . . .” 65 P.S. § 67.703.

4 Id. at 50a. The Department disagreed with Requesters that an exemption log or in camera review was necessary. Id. at 56a. Following a request from the OOR for additional evidence, the Department provided a supplemental affidavit from Podolak, in which Podolak clarified that records withheld by the Department related to a single non-criminal investigation. Id. at 80a. The results of this investigation prompted the Department’s February 4, 2022 notification to Permittees that they could no longer produce Products containing non-FDA approved additives and that existing Products containing non- approved additives were subject to mandatory recall procedures. Id. at 81a. The OOR issued a decision on March 1, 2022, which granted in part and denied in part Requesters’ appeal.5 C.R., Ex. 13 at 1. The OOR acknowledged that Requesters sought an in camera review of the Department’s records; however, the OOR felt it could decide the matter on the evidence presented. Id. at 5.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Department of Health v. Office of Open Records
4 A.3d 803 (Commonwealth Court of Pennsylvania, 2010)
Pennsylvania State Troopers Ass'n v. Scolforo
18 A.3d 435 (Commonwealth Court of Pennsylvania, 2011)
Wishnefsky v. Pa. Dep't of Corr.
144 A.3d 290 (Commonwealth Court of Pennsylvania, 2016)
Unitedhealthcare of Pa., Inc. v. Pa. Dep't of Human Servs.
187 A.3d 1046 (Commonwealth Court of Pennsylvania, 2018)
Office of the Governor v. Scolforo
65 A.3d 1095 (Commonwealth Court of Pennsylvania, 2013)
Commonwealth, Office of Open Records v. Center Township
95 A.3d 354 (Commonwealth Court of Pennsylvania, 2014)
McGowan v. Pennsylvania Department of Environmental Protection
103 A.3d 374 (Commonwealth Court of Pennsylvania, 2014)

Cite This Page — Counsel Stack

Bluebook (online)
J. Cassel & The Law Office of Hawke McKeon & Sniscak, LLP v. DOH (OOR), Counsel Stack Legal Research, https://law.counselstack.com/opinion/j-cassel-the-law-office-of-hawke-mckeon-sniscak-llp-v-doh-oor-pacommwct-2023.